You are here: Home » Markets » News
Business Standard

Dr Reddy's up 4% after receiving EIR from USFDA for Srikakulam Unit I

In past one month, the stock has outperformed the market by surging 17% as compared to 2% decline in the S&P BSE Sensex

SI Reporter  |  Mumbai 

reddy, dr reddy's
Dr Reddy's laboratory

has moved higher by 4% to Rs 2,409 on BSE in intra-day trade after the company received an Establishment Inspection Report (EIR) from the US health regulator for a unit of its plant in Andhra Pradesh.

“The company's formulation plant (SEZ) Unit I, Andhra Pradesh, have received an Establishment Inspection Report (EIR) from the US FDA,” said in BSE filing.

On June 16, 2017, the pharmaceutical company had said the issued a Form 483 with one observation on completion of audit of the above-referred facility.

Last week, Dr Reddy’s said that it had received from the for a unit II of its plant in Andhra Pradesh. It, however, did not state if the US health regulator had made any observation in the

In a separate filing the company said it had received zero observations for its custom pharmaceutical services facility, technology development centre, at Miyapur in Hyderabad after audit of the facility by the

In past one month, the stock has outperformed the market by surging 17% as compared to 2% decline in the S&P BSE Sensex.

First Published: Thu, September 28 2017. 11:23 IST
RECOMMENDED FOR YOU